Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Akums Drugs will undertake this development and commercialization in India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
